concentrations were measured using the Protein Assay kit (Biorad) according to the manufacturer's instructions. To partially denature proteins, guanidinium hydrochloride (final concentration 0.5 M) and acetonitrile (final concentration 2%) were added to the cleared protein extracts. 1 mg of the protein sample was digested overnight at 37°C using sequencing--grade, modified trypsin (Promega, Madison, WI, USA) (enzyme/substrate of 1/100 w/w). Samples were acidified with acidic acid to a final concentration of 0.5%. The digest was vacuum dried and the equivalent of 500 µg of the original protein material was loaded onto a RP--HPLC column for fractionation as described previously (4) . To prevent oxidation of methionines between RP--HPLC runs, methionines were oxidized in the injector compartment by transferring 20 μl of a freshly prepared aqueous 3% H2O2 solution to a vial containing 90 µl of the acidified peptide mixture (final concentration of 0.54% H2O2). This reaction proceeded for 30 min at 30°C. For chromatographic separation 100 µl peptide mixture was then immediately injected onto an RP--HPLC column (Zorbax ® 300SB--C18 Narrow--bore, 2.1 mm internal diameter × 150 mm length, 5 μm particles, Agilent). Following 10 min of isocratic pumping with solvent A (10 mM ammonium acetate in water/ACN (98:2 v/v), pH 5.5), a gradient of 1% solvent B increase per minute (solvent B: 10 mM ammonium acetate in ACN/water (70:30 v/v), pH 5.5) was started. The column was then run at 100% solvent B for 5 min, switched to 100% solvent A and re--equilibrated for 20 min. The flow was kept constant at 80 μl/min using Agilent's 1100 series capillary pump with the 100 μl/min flow controller. Fractions of 0.5 min were collected from 20 to 80 min after sample injection (120 fractions). These peptide fractions were vacuum dried and fractions eluting 12 min apart were pooled by re--dissolving these in a final volume of 40 µl of 2 mM TCEP and 2% acetonitrile, similar to a pooling strategy described previously (4) . In total, 24 samples were analyzed by LC--MS/MS. N--terminal COFRADIC analysis. For N--terminal COFRADIC analyses, HCT116 and mESC E14 cells were lysed in 50 mM HEPES pH 7.4, 100 mM NaCl and 0.8% CHAPS containing a cocktail of protease inhibitors (Roche) for 10 min on ice and centrifuged for 15 min at 16,000 g at 4°C and the protein samples subjected to N--terminal COFRADIC as described by Staes et al. (2011) (5) . To enable the assignment of in vivo Nt--acetylation events, all primary protein amines were blocked using a (stable isotopic encoded) N--hydroxysuccinimide ester at the protein level (i.e. NHS--13 C2D3--acetate) (6) . Per proteome, 45 samples were analyzed by LC--MS/MS. LC--MS/MS analysis. LC--MS/MS analysis was performed using an Ultimate 3000 RSLC nano LC--MS/MS system (Dionex, Amsterdam, The Netherlands) in--line connected to an LTQ Orbitrap Velos (Thermo Fisher Scientific, Bremen, Germany), for shotgun samples, or a LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany), for N--terminal COFRADIC samples. 2 µl of the sample mixture was first loaded on a trapping column (made in--house, 100 µm internal diameter (I.D.) × 20 mm length, 5 µm Reprosil-Pur Basic--C18--HD beads, Dr. Maisch, Ammerbuch--Entringen, Germany). After back--flushing from the trapping column, the sample was loaded on a reverse--phase column (made in--house, 75 µm I.D. × 150 mm length, 3 µm C18 Reprosil-Pur Basic--C18--HD beads). Peptides were loaded with solvent A' (0.1% trifluoroacetic acid in 2% acetonitrile) and were separated with a linear gradient from 98% of solvent A'' (0.1% formic acid in 2% acetonitrile) to 50% of solvent B' (0.1% formic acid in 80% acetonitrile) with a linear gradient of 1.8% of solvent B' increase per minute at a flow rate of 300 nl/min, followed by a steep increase to 100% of solvent B'. The Orbitrap Velos and LTQ Orbitrap XL mass spectrometers were operated in data--dependent mode, automatically switching between MS and MS/MS acquisition for the ten or six most abundant peaks in a MS spectrum respectively. Mascot Generic Files were created from the MS/MS data in each LC run using the Distiller software (version 2.3.2.0). Peptide/protein identification and interpretation. The protein and peptide searches were performed against our species--specific custom database with X! Tandem Sledgehammer (2013.09.01.1) and OMSSA 2.1.9 using the SearchGui (1.16.4) tool (7) . For the shotgun proteome analyses, methionine oxidation to methionine--sulfoxide, pyroglutamate formation of N--terminal glutamine and acetylation of the N--terminus were selected as variable modifications. For the HCT116 samples, heavy labelled arginine ( 13 C6) and lysine ( 13 C6) were additionally selected as fixed modifications. Mass tolerance was set to 10 ppm on precursor ions and to 0.5 Da on fragment ions. The peptide charge was set to 2+, 3+, 4+. Trypsin was selected as the cleavage enzyme with one missed cleavage allowed. Cleavage was also allowed when arginine or lysine was followed by proline. For the N--terminomics experiment, the generated MS/MS peak lists were searched with Mascot (version 2.3) (Mascot is compatible with the endoproteinase semi--Arg--C/P cleavage setting, see below). Mass tolerance on precursor ions was set to 10 ppm (with Mascot's C13 option set to 1) and to 0.5 Da on fragment ions. The peptide charge was set to 1+, 2+, 3+ and the instrument setting to ESI--TRAP. Methionine oxidation to methionine--sulfoxide, 13 C2D3--acetylation on lysines and carbamidomethylation of cysteine were set as fixed modifications. Variable modifications were 13 C2D3--acetylation, acetylation of peptide N--termini and pyroglutamate formation of N--terminal glutamine. For the HCT116 samples, 13 C6 15 N4 L--arg was additionally set as fixed modification. Endoproteinase semi--Arg--C/P (Arg--C specificity with arginine--proline cleavage allowed) was set as enzyme allowing for no missed cleavages.
Protein and peptide identification and data interpretation were done using the PeptideShaker algorithm (http://code.google.com/p/peptide--shaker, version 0.26.2), setting the FDR to 1% at all levels (peptide--to--spectrum matching, peptide and protein). Ribosome profiling (RIBO--seq). The RIBO--seq of the HCT116 cells was executed as follows. 100 µl of the clarified HCT116 cell lysate (equivalent to 4 × 10 6 cells) was used as input for ribosome footprinting. The A260 absorbance of the lysate was measured with Nanodrop (Thermo Scientific) and for each A260, 5 units of ARTseq Nuclease (Epd icentre) were added to the samples. The nuclease digestion proceeded for 45 min at room temperature and was stopped by adding SUPERase.In Rnase Inhibitor (Life Technologies). Next, the ribosome protected fragments (RPFs) were isolated using Sephacryl S400 spin columns (GE Healthcare) according to the procedure described in 'ARTseq Ribosome Profiling Kit, Mammalian' (Epicentre). The RNA was extracted from the samples using acid 125 phenol:24 chloroform:1 isoamyl alcohol and precipitated overnight at --20°C by adding 2 μl glycogen, 1/10th volume of 5 M ammonium acetate and 1.5 volumes of 100% isopropyl alcohol. After centrifugation at 18,840 × g and 4°C for 20 min, the purified RNA pellet was resuspended in 10 μl nuclease free water. Library preparation and sequencing. The HCT116 libraries were created according to the guidelines described in the ARTseq RIBO--seq Kit, Mammalian protocol (Epicentre). The RPFs were initially rRNA depleted using the Ribo--Zero Magnetic Kit (Human/Mouse/Rat, Epicentre), omitting the 50°C incubation step. Cleanup of the rRNA depletion reactions was performed through Zymo RNA Clean & Concentrator--5 kit (Zymo Research) using 200 μl binding buffer and 450 μl absolute ethanol. The samples were separated on a 15% urea--polyacrylamide gel and footprints of 26 to 34 nucleotides long were excised. RNA was extracted from the gel and precipitated. The pellet was resuspended in 20 μl nuclease--free water. Next, RPFs were end polished, 3' adaptor ligated, reverse transcribed and PAGE purified. 5 μl of circularized template DNA was used in the PCR reaction and amplification proceeded for 11 cycles. The libraries were purified with AMPure XP beads (Beckman Coulter) and their quality was assessed on a High Sensitivity DNA assay chip (Agilent technologies). The concentration of the libraries was measured with qPCR and they were single end sequenced on a Hiseq (Illumina) for 50 cycles. Raw sequencing reads of the mESC RIBO--seq data (8) were downloaded from the Gene Expression Omnibus (dataset GSE30839). All reads from the control (cycloheximide treated, also referred to as CHX treated, sample GSM765292) and harringtonine treated (also referred to as HARR treated, sample GSM765295) were used. Correlation analysis. Only the transcripts identified based on Swiss--Prot as well as our custom RIBO--seq derived translation products database were used for the correlation analysis. Quantification of ribosome occupancy was measured as ribosomal footprints per CDS (RPF count), hereby correcting for a possible 3'UTR and 5'UTR bias (8) . Two quantitative measures for protein abundance based on spectral counts (emPAI (9) and NSAF (10)) were calculated using the shotgun proteomics data. While the first method (protein abundance index (PAI)) uses the number of peptides per protein normalized by the theoretical number of peptides, the NSAF method takes both the protein length and the total number of identified MS/MS spectra in an experiment into account. For each protein transcript with an aTIS for which quantitative RIBO--seq and shotgun proteomics information was available, a Pearson correlation coefficient was calculated between its normalized RPF count (based on CDS length) and its normalized spectral count. When more than one RIBO--seq--derived transcript corresponded to a particular Swiss--Prot protein sequence, the one with the highest normalized RPF count was used. The different normalization and identification approaches were combined with the following additional transcript filtering settings: i) no extra cutoffs, ii) only aTIS transcripts with a validated MS/MS--based identification (meaning that the spectral count value was ≥2), iii) only aTIS transcripts with a total RPF count ≥ 200 and iv) only aTIS transcripts with both a validated MS/MS--based identification and an RPF count ≥ 200. All correlation coefficients were computed using log--transformed RPF and emPAI/NSAF measures. Data availability. All the MS data were converted using the PRIDE Converter (11) and are available through the PRIDE database (12) with the dataset identifier PXD000304 and DOI 10.6019/PXD000304 (for HCT116 MS experiments) and PXD000124 and DOI 10.6019/PXD000124 (for the mESC MS experiments). The mESC datasets are publicly available, while the HCT116 datasets require a login (http://www.ebi.ac.uk/pride/archive/login, PX reviewer account: username: review48267, password: TTewpyNH). The RIBO--seq libraries have been deposited in NCBI's Gene Expression Omnibus (13) and are accessible through the GEO series accession number GSE58207 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE58207).
Supplementary Figure S1
Mouse CHX Mouse HARR The MS/MS spectra and sequence fragmentations indicate the confidence and quality of the N--terminal peptide identifications. In both cases the N--terminus was found to be Nt--acetylated (ace--), a co--translational protein modification indicative of translation initiation, and the initiator methionine removed by the action of methionine aminopeptidase or MetAP.
Supplementary Figure S8
Supplementary Figure  S8| Correlation plots of RPF--counts (RIBO--seq) with NSAF--based protein abundance estimates for the proteins uniquely identified in Swiss--Prot. These proteins were not derived from RIBO--seq data, because the LTM treatment and/or TIS calling failed to identify these TISs. Correlations could still be calculated as the CHX treatment did result in detectable coverage for these transcripts. -
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